Figure 1.

Chronic Myeloid Leukemia (CML) Leukemic Stem Cells (LSC) pathways involved in tyrosine kinase inhibitor (TKI) resistance and potential therapeutic targets to impair them. LSC (in the center) is represented within its microenvironment and key interactions with different bone-marrow cells are shown. This figure is coupled with Table 1 for ex-vivo candidate molecules (yellow tags) and Table 2 for clinical trials involving candidate molecules (green tags) with their respective mode of action (red symbols).